Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyRegional therapyDiseaseHepatocellular CarcinomaSubgroupICD10C22.0MeSHCarcinoma, HepatocellularLiver DiseasesLiver NeoplasmsSequenceCheckMate 040: NIVO1/IPIL3, HCC (PID1788) -|- NIVO240, maint. (PID1789)HIMALAYA: TREM300/DURV1500, HCC, C1 (PID2288) -|- DURV1500, C2+ (PID2289)ChemotherapyChemo-substanceAtezolizumabBevacizumabCabozantinibCisplatinDoxorubicinDrug-Eluting BeadsDurvalumabEthiodized oilFluorouracilFolinic acidIodixanolIpilimumabLenvatinibMitomycinNaCl 0.9%NivolumabOxaliplatinPembrolizumabPolyvinyl alcoholRamucirumabRegorafenibSorafenibTremelimumabChemo-substanceAtezolizumabBevacizumabCabozantinibCisplatinDoxorubicinDrug-Eluting BeadsDurvalumabEthiodized oilFluorouracilFolinic acidIodixanolIpilimumabLenvatinibMitomycinNaCl 0.9%NivolumabOxaliplatinPembrolizumabPolyvinyl alcoholRamucirumabRegorafenibSorafenibTremelimumabChemo-substanceAtezolizumabBevacizumabCabozantinibCisplatinDoxorubicinDrug-Eluting BeadsDurvalumabEthiodized oilFluorouracilFolinic acidIodixanolIpilimumabLenvatinibMitomycinNaCl 0.9%NivolumabOxaliplatinPembrolizumabPolyvinyl alcoholRamucirumabRegorafenibSorafenibTremelimumabChemo-substanceAtezolizumabBevacizumabCabozantinibCisplatinDoxorubicinDrug-Eluting BeadsDurvalumabEthiodized oilFluorouracilFolinic acidIodixanolIpilimumabLenvatinibMitomycinNaCl 0.9%NivolumabOxaliplatinPembrolizumabPolyvinyl alcoholRamucirumabRegorafenibSorafenibTremelimumabNo. Substances12345 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideNo. Substances1237Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseInductionMaintenanceTherapy intentionpalliativeRisksAdrenal InsufficiencyAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaBleedingCardiotoxicityColitisDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueHand-Foot SyndromeHemorrhageHepatotoxicityHyperbilirubinemiaHyperkalemiaHypertensionHyperthyroidismHypophosphatemiaHypophysitisHypothyroidismIncrease AminotransferasesIncrease in lipaseInfusion ReactionMucositisNeutropeniaPancreatitisPneumonitisProteinuriaPruritusPyrexiaRashThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorAbou-Alfa GKBruix JCho SFinn RSKim HDKudo MLencioni RLlovet JMinKe HeYamada RYau TZhu ADiseasefortgeschrittenes Leberzellkarzinom, Erstlinie, ECOG 0-2HCC, nach Therapie mit Sorafenib, Child–Pugh A, ECOG 0-1HCC lokal fortgeschritten oder metastasiert, nicht operabel, BCLC B oder C, ChildPugh A, ECOG 0-1HCC mit Fernmetastasen oder einer Tumorlokalisation, die lokoregionär nicht kontrolliert oder reseziert werden kann, ChildPugh A, ECOG 0-1HCC mit Fernmetastasen oder nicht resektabelHCC nicht operabel, Child-Pugh A, ECOG 0-1, ErstlinientherapieHepatozelluläres Karzinom, größer 5cm, Zweitlinie nach DEB-TACE mit Hepasphereshepatozelluläres Karzinom, portal vein invasion, Child Pugh Class A, Erstlinie, ECOG 0-2hepatozelluläres Karzinom, Zweitlinie nach Sorafenib, Child-Pugh-Class A, ECOG 0-1Leberzellkarzinom, Zweitlinie nach Sorafenib, Child-Pugh A, ECOG 0-1Nicht resezierbares, nicht-metastasiertes hepatozelluläres Karzinomnichtresezierbares hepatozelluläres Karzinom, Erstlinie, ECOG 0-1OriginAsan Medical Center, Department of Radiology, University of Ulsan College of Medicine, Seoul, KoreaBarcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, IDIBAPS-Hospital Clinic de Barcelona, CIBERehd, Universitat de Barcelona, Catalonia, SpainDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, JapanDivision of Diagnostic Imaging and Intervention, Pisa University Hospital, University of PisaDivision of Vascular and Interventional Radiology, Department of Radiology, Medical University of South Carolina, Charleston, SC, USAGeffen School of Medicine at UCLA, Santa Monica, USA, IMbrave150Keynote 224Massachusetts General Hospital Cancer Center, Harvard Medical Center, Boston, REACH-2Memorial Sloan Kettering Cancer Center, New York, HIMALAYA trialMemorial Sloan Kettering Cancer Center, New York, USA, CELESTIAL trialSHARP investigator´s studySun Yatsen University Cancer Center, State KeyLaboratory of Oncology in SouthChinaUniversity of Hong Kong, China, CheckMate 040University of Ulsan College of Medicine, Seoul, Republic of Korea, RENOBATE trialProtocols in Revision 17 protocols foundProtocols under revision.Atezolizumab 1200 / Bevacizumab 15, Hepatocellular Carcinoma (PID1537 V1.0)Cabozantinib 60, Hepatocellular Carcinoma (PID1558 V1.2)cTACE - Cisplatin 2 / Ethiodized oil 12.8, Hepatocellular Carcinoma (PID2879 V1.0)cTACE - Mitomycin 10 / Ethiodized oil 6.4, Hepatocellular Carcinoma (PID2866 V1.0)DEB-TACE - Doxorubicin 75, Hepatocellular Carcinoma (PID2931 V1.0)Durvalumab 1500, Hepatocellular Carcinoma (PID2510 V1.0)Lenvatinib 12, Hepatocellular Carcinoma (PID79 V1.0)Nivolumab 1 / Ipilimumab 3 - Nivolumab 240, Hepatocellular Carcinoma, Maintenance (PID1789 V1.1)Nivolumab 1 / Ipilimumab 3, Hepatocellular Carcinoma (PID1788 V1.2)Nivolumab 480 / Regorafenib 80, Hepatocellular Carcinoma (PID2572 V1.0)Pembrolizumab 200, Hepatocellular Carcinoma (PID1376 V1.0)Ramucirumab 8, Hepatocellular Carcinoma (PID1400 V1.0)Regorafenib 160, hepatocellular carcinoma (PID248 V1.0)Sorafenib 400 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Hepatocellular Carcinoma (PID675 V1.0)Sorafenib 400, hepatocellular carcinoma (PID749 V1.1)Tremelimumab 300 / Durvalumab 1500 - Durvalumab 1500, Hepatocellular Carcinoma, Cycle 2+ (PID2289 V1.0)Tremelimumab 300 / Durvalumab 1500, Hepatocellular Carcinoma, Cycle 1 (PID2288 V1.0)
